Lipoprotein-associated phospholipase A2 is elevated in patients with severe aortic valve stenosis without clinically overt atherosclerosis

被引:20
作者
Kolasa-Trela, Renata [2 ]
Fil, Korneliusz [2 ]
Bazanek, Marta [2 ]
Grudzien, Grzegorz [1 ,2 ]
Sobczyk, Dorota [2 ]
Sadowski, Jerzy [1 ,2 ]
Undas, Anetta [1 ,2 ]
机构
[1] Jagiellonian Univ, Coll Med, Inst Cardiol, PL-31202 Krakow, Poland
[2] John Paul 2 Hosp, Krakow, Poland
关键词
aortic valve stenosis; inflammation; lipoprotein-associated phospholipase A(2); LOW-DENSITY-LIPOPROTEIN; CARDIOVASCULAR-DISEASE; CORONARY-DISEASE; HEART-DISEASE; RISK; LP-PLA(2); BIOMARKER;
D O I
10.1515/cclm-2012-0015
中图分类号
R446 [实验室诊断]; R-33 [实验医学、医学实验];
学科分类号
1001 ;
摘要
Background: Lipoprotein-associated phospholipase A(2) (Lp-PLA(2)) is an inflammatory mediator involved in atherosclerosis. Since aortic valve stenosis (AVS) is regarded as an atherosclerosis-like inflammatory disease, we sought to investigate whether AVS is associated with elevated Lp-PLA(2). Methods: Plasma Lp-PLA(2) levels were determined in 48 consecutive patients with severe AVS without atherosclerotic vascular disease and compared with the values obtained in 48 controls matched for age, sex and cardiovascular risk factors. Results: Lp-PLA(2) was higher in AVS than in controls (242.3 +/- 50.4 vs. 151.9 +/- 28.1 ng/mL, p < 0.0001). Lp-PLA(2) correlated inversely with aortic valve area (AVA) (r=-0.53; p=0.0001) and positively with mean pressure gradient (PG) (r=0.32; p=0.029). In multivariable analysis C-reactive protein (CRP) (OR=1.42; 95 % CI 0.95-2.1; p=0.09) and AVA (OR=0.003; 95 % CI 0.00004-0.23; p<0.01) were independently associated with Lp-PLA(2) above a mean of 242 ng/mL. After adjustment for CRP, AVA was the only independent predictor of Lp-PLA(2) in AVS patients (p<0.001). Conclusions: This study is the first to show that AVS is characterized by increased plasma Lp-PLA(2) levels associated with the severity of AVS, which suggests active involvement of Lp-PLA(2) in the pathogenesis of AVS.
引用
收藏
页码:1825 / 1831
页数:7
相关论文
共 32 条
[1]  
Ahmed Mohamed S., 2011, Inflammation & Allergy Drug Targets, V10, P236
[2]   Lipoprotein-associated phospholipase A2: a cardiovascular risk predictor and a potential therapeutic target [J].
Ali, Muzammil ;
Madjid, Mohammad .
FUTURE CARDIOLOGY, 2009, 5 (02) :159-173
[3]   Association of Carotid Plaque Lp-PLA2 with Macrophages and Chlamydia pneumoniae Infection among Patients at Risk for Stroke [J].
Atik, Berna ;
Johnston, S. Claiborne ;
Dean, Deborah .
PLOS ONE, 2010, 5 (06)
[4]   Echocardiographic Assessment of Valve Stenosis: EAE/ASE Recommendations for Clinical Practice [J].
Baumgartner, Helmut ;
Hung, Judy ;
Bermejo, Javier ;
Chambers, John B. ;
Evangelista, Arturo ;
Griffin, Brian P. ;
Iung, Bernard ;
Otto, Catherine M. ;
Pellikka, Patricia A. ;
Quinones, Miguel .
JOURNAL OF THE AMERICAN SOCIETY OF ECHOCARDIOGRAPHY, 2009, 22 (01) :1-23
[5]   Influence of race and sex on lipoprotein-associated phospholipase A2 levels: Observations from the Dallas Heart Study [J].
Brilakis, Emmanouil S. ;
Khera, Amit ;
McGuire, Darren K. ;
See, Raphael ;
Banerjee, Subhash ;
Murphy, Sabina A. ;
de Lemos, James A. .
ATHEROSCLEROSIS, 2008, 199 (01) :110-115
[6]   Lipoprotein-associated phospholipase A2 as a biomarker for coronary disease and stroke [J].
Caslake, MJ ;
Packard, CJ .
NATURE CLINICAL PRACTICE CARDIOVASCULAR MEDICINE, 2005, 2 (10) :529-535
[7]   Recent Developments with Lipoprotein-Associated Phospholipase A2 Inhibitors [J].
Chauffe, Ryan J. ;
Wilensky, Robert L. ;
Mohler, Emile R., III .
CURRENT ATHEROSCLEROSIS REPORTS, 2010, 12 (01) :43-47
[8]   Lipoprotein associated phospholipase A2: Role in atherosclerosis and utility as a biomarker for cardiovascular risk [J].
Colley K.J. ;
Wolfert R.L. ;
Cobble M.E. .
EPMA Journal, 2011, 2 (1) :27-38
[9]   Association between circulating oxidised low-density lipoprotein and fibrocalcific remodelling of the aortic valve in aortic stenosis [J].
Cote, C. ;
Pibarot, P. ;
Despres, J-P ;
Mohty, D. ;
Cartier, A. ;
Arsenault, B. J. ;
Couture, C. ;
Mathieu, P. .
HEART, 2008, 94 (09) :1175-1180
[10]   Consensus panel recommendation for incorporating lipoprotein-associated phospholipase A2 testing into cardiovascular disease risk assessment guidelines [J].
Davidson, Michael H. ;
Corson, Marshall A. ;
Alberts, Mark J. ;
Anderson, Jeffrey L. ;
Gorelick, Philip B. ;
Jones, Peter H. ;
Lerman, Amir ;
McConnell, Joseph P. ;
Weintraub, Howard S. .
AMERICAN JOURNAL OF CARDIOLOGY, 2008, 101 (12A) :51F-57F